Meeting
2023 ASCO Gastrointestinal Cancers Symposium
ETCTN 10476: A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.
Authors
Thatcher Ross Heumann
Vanderbilt Ingram Cancer Center, Nashville, TN;
Thatcher Ross Heumann , Mark Yarchoan , Judy Murray , Hao Wang , John Joseph Wright , Elad Sharon , Gregory B. Lesinski , Nilofer Saba Azad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04941287
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS639)
DOI
10.1200/JCO.2023.41.4_suppl.TPS639
Abstract #
TPS639
Poster Bd #
P8
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166.
First Author: Stephen V. Liu
Poster
2019 ASCO Annual Meeting
Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
First Author: Adam Brufsky
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Expanding immunotherapy options in cholangiocarcinoma: Role of CD27 agonist in combination with PD-L1 and MEK inhibition on antitumor effect and CD8+ T cells.
First Author: Frances Jenkins Bennett
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Tinengotinib (TT-00420) in combination with atezolizumab in Chinese patients (pts) with biliary tract carcinoma (BTC): Preliminary efficacy and safety results from a phase Ib/II study.
First Author: Panpan Zhang